Shots:

• Blackstone to invest $2B in Alnylam that includes $1B in committed payments in exchange of 50% royalties and commercial milestones for inclisiran- ~$750M in a first lien senior secured term loan led by GSO- ~$150M for Alnylam’s cardiometabolic programs (vutrisiran and ALN-AGT) and ~$100M on purchase of Alnylam’s common stock
• The transaction marks the third deal major deal for Blackstone Life Sciences- with the first one as the acquisition of Clarus in late 2018 and second as the launch of CV company- Anthos with Novartis- and established FerGene to advance bladder cancer therapy- with Ferring Pharmaceuticals
• Inclisiran is an investigational RNAi therapeutic to treat hypercholesterolemia- currently under the US FDA’s review and has been evaluated in P-III program to reduce LDL

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pharma Advancement